Cisapride (R 51619): Transforming Cardiac Electrophysiology
2026-05-21
Cisapride (R 51619) bridges molecular pharmacology and phenotypic screening, enabling highly sensitive detection of cardiotoxicity and arrhythmia risk in human stem cell-derived cardiomyocytes. APExBIO delivers unmatched solubility, QC, and workflow reproducibility—making Cisapride the gold standard for cardiac electrophysiology research and hERG channel inhibition assays.
Ruxolitinib Targets DRP1-Mediated Mitochondrial Fission in A
2026-05-20
The referenced study reveals that ruxolitinib, by inhibiting DRP1-mediated mitochondrial fission through suppression of the JAK1/2-STAT3 pathway, induces both apoptosis and pyroptosis in anaplastic thyroid carcinoma (ATC) cells. These findings offer mechanistic insight into mitochondrial dynamics as a therapeutic target in aggressive thyroid cancers and support new avenues for apoptosis detection and mitochondrial dysfunction research.
Pioglitazone: PPARγ Agonist Workflows for Metabolic & Inflam
2026-05-20
Pioglitazone stands out as a selective PPARγ agonist, enabling researchers to dissect metabolic and inflammatory pathways with precision. This article translates recent mechanistic advances and experimental benchmarks into clear, actionable protocols and troubleshooting tips—empowering reproducible discovery in diabetes, neurodegeneration, and immune modulation.
Deferasirox Fe3+ Chelate: Workflows for Iron Overload Resear
2026-05-19
Deferasirox Fe3+ chelate empowers researchers with a DMSO-soluble, high-purity tool for dissecting iron overload mechanisms in beta-thalassemia and chronic anemia models. This article demystifies protocol optimization, comparative advantages, and troubleshooting strategies for maximizing the impact of Exjade-based iron chelation studies.
Evaluating Phebestin: A Novel Aminopeptidase Inhibitor Again
2026-05-19
The reference study introduces phebestin, a bestatin-related aminopeptidase inhibitor, as a potent agent against both chloroquine-sensitive and -resistant Plasmodium falciparum at nanomolar concentrations. Its efficacy in vitro and in vivo, alongside low cytotoxicity, highlights phebestin’s potential as a new chemotherapeutic target for malaria, offering insight into peptidase inhibition as a promising strategy amid rising drug resistance.
CRISPR Editing of LGMN Suppresses Breast Cancer Metastasis
2026-05-18
This study demonstrates that co-delivery of Cas9 mRNA and guide RNAs targeting the LGMN gene impairs metastatic potential in breast cancer cells. The findings highlight a robust T7 RNA polymerase transcription workflow for generating functional RNA components and suggest new avenues for RNA-based cancer therapeutics.
Palomid 529: Precision PI3K/Akt/mTOR Inhibition for Cancer R
2026-05-18
Palomid 529 (P529) offers researchers a robust tool for dissecting and targeting the PI3K/Akt/mTOR signaling axis in both cancer and neural models. Its dual mTORC1/mTORC2 inhibition, validated antitumor potency, and compatibility with radiotherapy and angiogenesis assays distinguish it for advanced experimental workflows.
Deferasirox Fe3+ Chelate: Precision in Iron Overload Researc
2026-05-17
Deferasirox Fe3+ chelate (Exjade) delivers high reproducibility and solubility for modeling iron overload in beta-thalassemia and chronic anemia research. Its robust chelation efficiency and workflow compatibility empower advanced studies in iron metabolism and lysosomal cell death.
Oteseconazole (VT-1161): Precision Antifungal Profiling for
2026-05-16
Explore the advanced antifungal mechanism and selectivity of Oteseconazole (VT-1161) against Candida species, including fluconazole-resistant strains. This article delivers deep insights into assay design, resistance management, and how Oteseconazole reshapes antifungal research workflows.
Revisiting Sumatriptan Metabolism: CYP and MAO Pathways Unve
2026-05-15
This study challenges the conventional view of sumatriptan metabolism, demonstrating that cytochrome P450 enzymes (CYP1A2, CYP2C19, CYP2D6) contribute to N-demethylation alongside MAO A-mediated deamination. These findings refine our understanding of metabolic pathways relevant to basic amine-containing drugs and inform the design of neurodegenerative disease models.
GOT1 Inhibition Disrupts Redox Homeostasis in Pancreatic Can
2026-05-15
This study identifies ziprasidone as a novel non-competitive inhibitor of glutamate-oxaloacetate transaminase 1 (GOT1), disrupting glutamine metabolism and redox balance in pancreatic ductal adenocarcinoma (PDAC) cells. These findings highlight GOT1 as a promising therapeutic target in PDAC and reinforce the importance of redox regulation in tumor biology.
Phosphoproteomic Adaptation in RCC Under Chronic Cabozantini
2026-05-14
This study uncovers how acute versus chronic Cabozantinib (XL184) exposure distinctly remodels phosphorylation networks and cell motility in renal cell carcinoma (RCC) models. By integrating quantitative phosphoproteomics and functional assays, the research provides a detailed systems-level view of adaptation to prolonged receptor tyrosine kinase inhibition, with implications for resistance mechanisms and study design in RCC.
Z-VAD-FMK: Precise Pan-Caspase Inhibition for Apoptosis Rese
2026-05-14
Z-VAD-FMK is a potent, cell-permeable, irreversible pan-caspase inhibitor essential for apoptosis pathway studies. It blocks pro-caspase-3 activation, enabling precise apoptosis inhibition in diverse cell lines. Its specificity and reproducibility make it a benchmark tool in immune and cancer research.
PCMT1 Drives Ovarian Cancer Metastasis: Genome-wide CRISPR I
2026-05-13
Zhang et al. employed a genome-wide CRISPR/Cas9 screen to identify PCMT1 as a key driver of anoikis resistance and metastasis in ovarian cancer. Their work reveals novel mechanistic links between PCMT1, extracellular matrix interactions, and focal adhesion signaling, highlighting therapeutic opportunities and methodological advances for cancer research.
Elbasvir–Grazoprevir: Advances in HCV Genotype 1 and 4 Thera
2026-05-13
This article reviews a pivotal study on the Elbasvir and Grazoprevir combination in the treatment of hepatitis C, highlighting its innovative dual-targeting mechanism and strong efficacy in diverse patient populations. The study’s findings are interpreted in the context of resistant HCV genotypes, comorbid conditions like CKD, and real-world clinical applicability.
459 records 18/31 page Previous Next First page 上5页 1617181920 下5页 Last page